Experimental Antibody Reduces Risk of C. difficile Recurrence
An experimental antibody developed by Merck & Co Inc. was shown in pivotal studies to reduce by…
C. diff
-
Experimental Antibody Reduces Risk of C. difficile Recurrence
An experimental antibody developed by Merck & Co Inc. was shown in pivotal studies to reduce by... -
New Treatment for Recurrent C. difficile Shows Promise
Giving people harmless spores of Clostridium difficile by mouth proved safe and effective in stopping recurrent bouts... -
C. Difficile, Monospot Tests Often Not Effective in Pediatric Patients
As educators, we love—and are always humbled by—those moments when we get to say, “I don’t know.”...
New Treatment for Recurrent C. difficile Shows Promise
Giving people harmless spores of Clostridium difficile by mouth proved safe and effective in stopping recurrent bouts…
C. Difficile, Monospot Tests Often Not Effective in Pediatric Patients
As educators, we love—and are always humbled by—those moments when we get to say, “I don’t know.”…
Loading ...